Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, Brock K, De Lavallade H, Craddock C, Clark RE, Smith ML, Fletcher R, Bishop R, Milojkovic D, Yap C. Copland M, et al. Among authors: craddock c. Lancet Haematol. 2022 Feb;9(2):e121-e132. doi: 10.1016/S2352-3026(21)00370-7. Epub 2021 Dec 11. Lancet Haematol. 2022. PMID: 34906334 Clinical Trial.
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.
Kanfer EJ, McGuigan D, Samson D, Abboudi Z, Abrahamson G, Apperley JF, Chilcott S, Craddock C, Davis J, MacDonald C, Macdonald D, Olavarria E, Philpott N, Rustin GJ, Seckl MJ, Sekhar M, Stern S, Newlands ES. Kanfer EJ, et al. Among authors: craddock c. Br J Cancer. 1998 Oct;78(7):928-32. doi: 10.1038/bjc.1998.603. Br J Cancer. 1998. PMID: 9764585 Free PMC article. Clinical Trial.
Immunotherapy for chronic myeloid leukaemia.
Apperley JF, Dazzi F, Craddock C, Goldman JM. Apperley JF, et al. Among authors: craddock c. Hematol Cell Ther. 1998 Oct;40(5):229-32. Hematol Cell Ther. 1998. PMID: 9844817 Review. No abstract available.
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis.
Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, Brookes P, de la Fuente J, Kanfer E, Apperley JF, Goldman JM. Craddock C, et al. Br J Haematol. 2001 Jan;112(1):228-36. doi: 10.1046/j.1365-2141.2001.02519.x. Br J Haematol. 2001. PMID: 11167809 Free article.
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.
Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, van Rhee F, Kaeda J, Cross NC, Craddock C, Kanfer E, Apperley J, Goldman JM. Mughal TI, et al. Among authors: craddock c. Br J Haematol. 2001 Dec;115(3):569-74. doi: 10.1046/j.1365-2141.2001.03155.x. Br J Haematol. 2001. PMID: 11736937 Free article.
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH. Lush RJ, et al. Among authors: craddock cf. Cytotherapy. 2001;3(3):203-10. doi: 10.1080/146532401753174034. Cytotherapy. 2001. PMID: 12171727 Clinical Trial.
416 results